AXER-204 in Participants With Chronic Spinal Cord Injury
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Chronic Spinal Cord Injury
In brief
This two-part trial will assess the safety, tolerability, pharmacokinetics, and efficacy of AXER-204 administered by lumbar puncture and slow bolus infusion. Part 1 will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of AXER-204. Part 2 will evaluate the safety, tolerability, pharmacokinetics, and efficacy of repeated doses AXER-204 in comparison to placebo.
Key facts
- Study ID
- NCT03989440
- Run by
- ReNetX Bio, Inc.
- People needed
- 52
- Starts
- 2019-07-16
- Expected to finish
- 2022-06-21
- Last updated by the study team
- 2023-08-22
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Keck Medicine of USC — Los Angeles, California, United States
- Shepherd Center — Atlanta, Georgia, United States
- Shirley Ryan AbilityLab / Northwestern — Chicago, Illinois, United States
- Spaulding Rehabilitation — Boston, Massachusetts, United States
- The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.